Is binge eating associated with poor weight loss outcomes in people with a high body weight? A systematic review with meta-analyses.

"Declarations Competing interestsAmanda Sainsbury and Zubeyir Salis own 50% each of the shares in Zuman International, a company that receives royalties and other payments for educational resources and services about adult weight management and research methodology. Amanda Sainsbury has also received presentation fees and travel reimbursements from Eli Lilly and Co, the Pharmacy Guild of Australia, Novo Nordisk, the Dietitians Association of Australia, Shoalhaven Family Medical Centres, the Pharmaceutical Society of Australia, and Metagenics, and served on the Nestlé Health Science Optifast VLCD advisory board from 2016 to 2018. Phillipa Hay receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and HETI New South Wales Institute of Psychiatry and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia and was a Member of the ICD-11 Working Group for Eating Disorders (2012–2019), and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract for Shire Pharmaceuticals regarding Binge Eating Disorder (July 2017) and consulting fees for the education of doctors from Takeda Pharmaceuticals. All views in this paper are her own. Author A and B declare they have no financial interests. Competing interests Amanda Sainsbury and Zubeyir Salis own 50% each of the shares in Zuman International, a company that receives royalties and other payments for educational resources and services about adult weight management and research methodology. Amanda Sainsbury has also received presentation fees and travel reimbursements from Eli Lilly and Co, the Pharmacy Guild of Australia, Novo Nordisk, the Dietitians Association of Australia, Shoalhaven Family Medical Centres, the Pharmaceutical Society of Australia, and Metagenics, and served on the Nestlé Health Science Optifast VLCD advisory board from 2016 to 2018. Phillipa Hay receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and HETI New South Wales Institute of Psychiatry and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia and was a Member of the ICD-11 Working Group for Eating Disorders (2012–2019), and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract for Shire Pharmaceuticals regarding Binge Eating Disorder (July 2017) and consulting fees for the education of doctors from Takeda Pharmaceuticals. All views in this paper are her own. Author A and B declare they have no financial interests."

"Funding Open access funding provided by University of Geneva This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (Grant numbers 2018/18028-2, 2020/04181-3, 2019/14622-0); National Health and Medical Research Council (Grant number 1135897)."